Lyra provides wet-lab software and analytics for CRISPR-based cell therapies, helping researchers design off-target-free edits and predict manufacturing yield. The platform integrates with sequencing data and lab equipment APIs to reduce time-to-clinic by 6 months per therapy. Spun out from Monash Biomedical Discovery Institute, Lyra has partnered with two cell therapy companies in the Asia-Pacific region.